BioAge Stock Rallies 29% Following Upsized $198M IPO
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Eli Lilly Unusual Options Activity
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Analyst Expectations For Amgen's Future
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Novo Nordisk, Lilly Weight Loss Drugs Poised for Price Reductions: Cantor's Louise Chen
Baird Reiterates Underperform on Amgen, Maintains $215 Price Target
Amgen Analyst Ratings
Amgen Shares Are Trading Lower After Following Atopic Dermatitis Data, Which Some Analysts Noted Did Not Meet Expectations Amid Competition in the Market.
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
The "gunpowder smell" of the USA election is getting stronger! Reports of shots fired at and damage to Harris' campaign team, with no injuries.
At the same time, Trump is also focusing a lot of energy on economic policies, but some economists warn that Trump's tariffs and large-scale expulsion plan may lead to soaring prices.
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
US stocks closed: S&P, Dow hit new highs again. Chinese concept stocks staged a 'Golden Dragon Soaring'.
①The three major indices collectively closed higher, with the S&P 500 Index and the Dow hitting new highs; ②Chinese concept stocks generally rose, with the Nasdaq Golden Dragon Index in China up by 9.13%; ③Nvidia rose by about 4%, and Huang Renxun temporarily ended the sell-off; ④The US Department of Justice sued Visa, accusing it of illegal monopoly.
Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS